Doxycycline †Rx
Doxy targets mito ribosomes/OXPHOS (CSC-selective), inhibits MMPs for anti-invasion, lowers efflux for chemo boost. Human pilots in breast/lung; moderate evidence—monitor photosens/GI/resistance.
Forms: Oral capsules/tablets (Rx, 100–200 mg)
Simple Summary
An antibiotic that targets tumor mitochondria (especially in stem-like cells) and blocks MMPs that tumors use to invade. Human pilot data exist; larger trials are needed.
Evidence at a glance
Early human pilots/trials supportive; preclinical mechanistic strong; larger confirmatory RCTs ongoing/pending.
How it may work
Doxycycline inhibits mitochondrial ribosomes, reducing OXPHOS and preferentially impairing cancer stem cells. It also inhibits MMP-2/-9 to reduce invasion/metastasis, can lower drug efflux (e.g., P-gp), and triggers ROS-linked apoptosis.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
- MMP-2/-9↓Inhibits gelatinases; reduces invasion/metastasis
- CSC Self-Renewal↓Preferential mito impairment in stem-like cells
- Mitochondrial OXPHOS↓Via ribosomal inhibition; ROS ↑
- Apoptosis↑ROS-linked; P-gp efflux ↓ for chemo synergy
- P-glycoprotein↓Enhances drug retention/sensitivity
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Paclitaxel: Tumor sensitivity ↑ in lung via efflux ↓.
- Metformin: CSC targeting in breast.
- Berberine: MMP inhibition in CRC.
- Resveratrol: CSC/apoptosis in breast.
- EGCG: ROS/chemo sensitivity in lung.
- Quercetin: MMP/apoptosis in pancreatic.
Overlapping mechanisms
- Mito ↓ / CSC ↓ / MMP ↓: Avoid excess stacking with other mito/CSC/MMP agents; risk resistance/amplified GI/toxicity.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- Dairy/antacids/iron (polyvalent cations)SeparateModerateTheoreticalChelation reduces absorption.
- Retinoids (e.g., isotretinoin)AvoidSevereTheoreticalIncreased intracranial pressure risk.
- Paclitaxel / Other chemoConsiderBeneficialTheoreticalEfflux inhibition; sensitivity ↑ in lung.
- Metformin / Berberine / Resveratrol / EGCG / QuercetinConsiderBeneficialTheoreticalCSC/MMP/ROS/apoptosis synergies in breast/lung/CRC/pancreatic.
Timing
- With food (non-dairy): Reduces GI upset; full glass water, upright.
- BID dosing: Steady levels; e.g., 100 mg AM/PM.
- Cycled (optional): E.g., 28 on/7 off to limit resistance.
References
Research
No published studies for Doxycycline yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 100–200 mg (po) Repurposing: 100 mg BID (total 200 mg/day). Pilot trials (e.g., breast cancer): 200 mg/day continuous. HED from animals (e.g., mouse 10–40 mg/kg) ~0.8–3.2 mg/kg (~56–224 mg for 70 kg); clinical uses align at lower end., Rx required. Take with full glass of water, upright to avoid esophagitis. Cycles (e.g., 28 days on/7 off) in some protocols to mitigate resistance. Strict clinician oversight; monitor for photosensitivity, GI, resistance..
Trials studying Doxycycline †Rx
No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →
Appears in these protocol claims
Doxycycline †Rx is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
- Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.
- Jane McLelland / Metabolic Blocking Claims : Multi-pathway metabolic strategy based around starving cancer fuel routes and blocking escape pathways.
- Care Oncology-Style Repurposed Drug Claims : Clinic-associated repurposed-drug approach often discussed around four common medications.